These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 18326882

  • 1. New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients.
    Chadban S.
    Nephrol Dial Transplant; 2008 Jun; 23(6):1816-8. PubMed ID: 18326882
    [No Abstract] [Full Text] [Related]

  • 2. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature.
    Ghisdal L, Bouchta NB, Broeders N, Crenier L, Hoang AD, Abramowicz D, Wissing KM.
    Transpl Int; 2008 Feb; 21(2):146-51. PubMed ID: 17971033
    [Abstract] [Full Text] [Related]

  • 3. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
    Porrini E, Delgado P, Alvarez A, Cobo M, Pérez L, González-Posada JM, Hortal L, Gallego R, García JJ, Checa M, Morales A, Salido E, Hernández D, Torres A.
    Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
    [Abstract] [Full Text] [Related]

  • 4. Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression.
    Hoitsma AJ, Hilbrands LB.
    Clin Transplant; 2006 Apr; 20(5):659-64. PubMed ID: 16968494
    [Abstract] [Full Text] [Related]

  • 5. [Frequency of T-cell mediated rejection in new-onset diabetes after kidney transplantation].
    Borda B, Szederkényi E, Lengyel C, Várkonyi T, Hódi Z, Kemény É, Szabó V, Lázár G.
    Orv Hetil; 2015 May 10; 156(19):785-9. PubMed ID: 26039918
    [Abstract] [Full Text] [Related]

  • 6. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation.
    Roland M, Gatault P, Doute C, Büchler M, Al-Najjar A, Barbet C, Chatelet V, Marlière JF, Nivet H, Lebranchu Y, Halimi JM.
    Transpl Int; 2008 Jun 10; 21(6):523-30. PubMed ID: 18266773
    [Abstract] [Full Text] [Related]

  • 7. Kidney transplant recipients and the incidence of adverse reactions to cyclosporin.
    Tolou-Ghamari Z, Palizban AA.
    Saudi Med J; 2004 Oct 10; 25(10):1499-500. PubMed ID: 15494834
    [No Abstract] [Full Text] [Related]

  • 8. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation.
    Ramos-Cebrián M, Torregrosa JV, Gutiérrez-Dalmau A, Oppenheimer F, Campistol JM.
    Transplant Proc; 2007 Sep 10; 39(7):2251-3. PubMed ID: 17889154
    [Abstract] [Full Text] [Related]

  • 9. New-onset diabetes after transplantation.
    Marchetti P.
    J Heart Lung Transplant; 2004 May 10; 23(5 Suppl):S194-201. PubMed ID: 15093805
    [Abstract] [Full Text] [Related]

  • 10. Acute rejection and heart infection rates in FK 506- versus cyclosporine A-treated heart transplant recipients: an endomyocardial biopsy pathologic study.
    Arbustini E, Dal Bello B, Rinaldi M, Diegoli M, Grasso M, Pellegrini C, Morbini P, Martinelli L, Bonora MR, Viganò M.
    J Heart Lung Transplant; 1997 Sep 10; 16(9):982-4. PubMed ID: 9322152
    [No Abstract] [Full Text] [Related]

  • 11. Diabetes mellitus after kidney transplantation: a French multicentre observational study.
    Kamar N, Mariat C, Delahousse M, Dantal J, Al Najjar A, Cassuto E, Lefrançois N, Cointault O, Touchard G, Villemain F, Di Giambattista F, Benhamou PY, Diapason Study Group.
    Nephrol Dial Transplant; 2007 Jul 10; 22(7):1986-93. PubMed ID: 17400559
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus.
    Pérez-Flores I, Sánchez-Fructuoso A, Calvo N, Valga EF, Barrientos A.
    Transplant Proc; 2010 Oct 10; 42(8):2902-4. PubMed ID: 20970565
    [Abstract] [Full Text] [Related]

  • 14. [What happens to a child after kidney transplant?].
    Qvist E, Rönnholm K, Holmberg C.
    Duodecim; 2006 Oct 10; 122(2):197-9. PubMed ID: 16509068
    [No Abstract] [Full Text] [Related]

  • 15. New-onset diabetes after liver transplantation: from pathogenesis to management.
    Marchetti P.
    Liver Transpl; 2005 Jun 10; 11(6):612-20. PubMed ID: 15915488
    [Abstract] [Full Text] [Related]

  • 16. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 17. Post-transplant diabetes mellitus: the last 10 years with tacrolimus.
    Bäckman LA.
    Nephrol Dial Transplant; 2004 Dec 27; 19 Suppl 6():vi13-vi16. PubMed ID: 15575021
    [Abstract] [Full Text] [Related]

  • 18. [The incidence, clinical implications, and risk factors of diabetes mellitus].
    Secchi A.
    G Ital Nefrol; 2003 Dec 27; 20 Suppl 25():S7-10. PubMed ID: 14523906
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW, Chudzinski R.
    Transplantation; 2009 Jan 27; 87(2):164-5. PubMed ID: 19155968
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.